Stopping a GLP-1 Medication: What the Research Shows and Why a Plan Matters
GLP-1 medicines such as semaglutide (Wegovy) and the dual GIP/GLP-1 medicine tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults, alongside nutrition and physical activity (FDA label, Wegovy; FDA label, Zepbound). For many people they bring real improvements in health.
People stop these medicines for many reasons: side effects, cost, a change in insurance, or reaching a goal they set with their clinician. Stopping can be the right decision. The research suggests that how you stop matters, and that a plan and steady support make a difference.
What happens to weight after stopping
Several well-designed studies have looked at this question.
- Semaglutide (STEP 1 extension). Adults lost an average of 17.3% of body weight over 68 weeks. Then both the medicine and the lifestyle program stopped. One year later, they had regained about two-thirds of the weight they had lost (Wilding et al., 2022).
- Tirzepatide (SURMOUNT-4). After an average loss of 20.9% over 36 weeks, 670 adults were randomly assigned to keep taking tirzepatide or switch to placebo. Over the next year, the placebo group regained 14% of their body weight, while the group that continued lost a further 5.5% (Aronne et al., 2024).
- All weight-management medicines (2026 review). Pooling 37 studies and more than 9,000 people, researchers found average regain of about 0.4 kg (just under 1 pound) a month after stopping. Regain was faster than after stopping behavioral weight programs (West et al., 2026).
Many people regain weight after stopping. That reflects how the body regulates weight over time, not a lack of effort. The STEP 1 authors concluded that obesity behaves like a chronic condition that often needs ongoing care (Wilding et al., 2022).
Health markers can drift back, too
Weight is only one part of the picture. In the STEP 1 extension, most improvements in blood pressure, cholesterol, blood sugar and related markers moved back toward where they started within a year of stopping (Wilding et al., 2022). The 2026 review projected that these markers return to baseline within about 1.4 years (West et al., 2026).
For people with type 2 diabetes, there is an added consideration. A large study of veterans with type 2 diabetes compared people who kept taking a GLP-1 medicine with people who stopped. Stopping was linked to a modestly higher risk of heart attack, stroke or death, and the gap grew the longer people were off treatment (Xie et al., 2026). This was an observational study of people with diabetes, so it does not tell us the same holds for people without diabetes. It is one more reason to decide about stopping together with the clinician who manages your diabetes.
Weight loss includes some lean mass
When people lose a substantial amount of weight, by any method, some of it is lean (muscle) mass. In a body-scan substudy of the SURMOUNT-1 trial, about 75% of the weight lost on tirzepatide was fat and about 25% was lean mass. That was the same proportion seen in the placebo group, who lost weight through nutrition and activity alone (Look et al., 2025).
So lean-mass loss is not unique to these medicines. It is a normal part of losing weight, and it is worth tracking, especially for anyone who wants to stay strong and active.
What helps: support around the medication
The strongest evidence that support matters comes from a Danish trial called S-LiTE. Adults who had just lost weight were assigned to an exercise program, the GLP-1 medicine liraglutide, both, or neither. After a year, the combination kept weight off better than either alone and reduced body fat about twice as much (Lundgren et al., 2021).
The researchers followed up one year after all treatment ended. People who had exercised alongside the medicine kept more of their weight loss than people who had taken the medicine alone (Jensen et al., 2024).
Notice, too, that in the STEP 1 extension the lifestyle program stopped at the same time as the medicine. And the authors of the 2026 review advised caution about short-term use of these medicines without a more comprehensive approach (West et al., 2026).
How Healthy Weight for Life is designed around these risks
Our Healthy Weight for Life program addresses the connection between weight and psychiatric illness. It uses name-brand GLP-1 and GIP/GLP-1 medicines, never compounded versions, inside a hands-on program built for the long term.
- It starts with an evaluation with Dr. Mee. Every patient begins with a physician evaluation, so the plan fits the whole person, including mental health and current medications.
- Phase 1: weekly visits during active weight change. Dosing is adjusted within protocol and informed by your biometric results.
- Body-composition scans focused on fat versus lean mass. Bioelectrical impedance body-composition scans, done 1 to 4 times a month, estimate how much of your weight is fat and how much is lean mass. They are less precise than a DXA scan, but they are useful for tracking trends in fat and lean mass over time, which is exactly the change the research says to watch. Vital signs are checked 1 to 4 times a month, with labs as needed.
- Nurse counseling after every scan. After each scan you meet with the program's registered nurse to talk through eating patterns, changes in your routine, life stressors and exercise, with encouragement and practical support. This mirrors what S-LiTE suggests: structure around the medicine, especially physical activity, matters.
- Phase 2: monthly maintenance. Monthly visits and personalized dosing to help keep your health gains steady.
- A planned exit. When you reach your goal, you choose the next step with your care team: a customized taper that brings the dose to zero, continuing Phase 1 and reassessing later, or moving to Phase 2. Research on the best way to taper is still limited, so we treat the taper as our careful, monitored approach, not a proven fix.
Our practice also offers vitamin supplementation services, including IM vitamin injections when clinically appropriate. They are available à la carte to all of our patients, and Healthy Weight for Life patients can add them as an option.
No program can promise that weight or muscle will stay exactly where it is. Healthy Weight for Life is designed to monitor for these changes early and to reduce the risks, with a clinical team watching the trends with you.
If you are thinking about stopping
- Talk with your prescriber before you stop or change your dose.
- Ask what will be monitored afterward, such as weight, blood pressure, blood sugar and cholesterol.
- Keep regular physical activity in your routine, the factor with the strongest evidence in the S-LiTE follow-up.
- If you have type 2 diabetes, plan the decision with the clinician who manages your diabetes.
- Decide in advance when you will check in and what would prompt a change of plan.
Talk with us
If you are considering a GLP-1 medicine, or thinking about stopping one, we can help you plan either step. Healthy Weight for Life is offered at our Los Alamitos office at 3662 Katella Ave. Request a consultation, email smee@asperahealth.com, or call (562) 431-9999.
This article is for general education and is not medical advice. Please don't stop or change any medication without talking with your prescriber.
Steven Mee, MD, is the Founder & Medical Director of Aspera & Applied Innovative Psychiatry in Los Alamitos, California. He earned his MD at the UC Irvine School of Medicine (1999) and completed his psychiatry residency at UC Irvine (1999–2003), where he served as Chief Resident. He then held a Della Martin postdoctoral research fellowship. He is a two-time NARSAD Young Investigator awardee, including the Arthur Zankel Memorial Investigator award (2005), and was principal investigator on nearly $1 million in federal VA research funding. He has served as a peer reviewer for the American Journal of Psychiatry. His co-authored research on psychological pain has appeared in PLOS ONE, the Journal of Psychiatric Research and Medical Research Archives. His clinical focus is neuropsychiatry and psychopharmacology. Read Dr. Mee's full bio →
& Applied Innovative Psychiatry